Bank Of Montreal Travere Therapeutics, Inc. Transaction History

Bank Of Montreal

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.26 - $8.28 $399,333 - $628,609	75,919 New	75,919 $624,000
Q1 2022 May 12, 2022	SELL	$23.61 - $30.6 $160,500 - $208,018	-6,798 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$24.34 - $31.17 $165,463 - $211,893	6,798 New	6,798 $206,000
Q3 2021 Nov 12, 2021	SELL	$12.98 - $25.03 $1.63 Million - $3.14 Million	-125,437 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$14.11 - $26.4 $1.77 Million - $3.31 Million	125,437 New	125,437 $1.88 Million

192

84.5M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.14B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.